ArticleAmerican journal of cancer research2025
LncRNA XIST enhances gastric cancer cell function by regulating STAT3/PD-L1 axis as a competing endogenous RNA for miR-124.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long non-coding RNA (lncRNA) XIST drives TGF-β-induced renal cancer progression via miR-141-3p/ZEB1 signaling.Translational andrology and urology · 2026Article
- Multifaceted roles of miR‑124 in cancer: Molecular mechanisms and clinical prospects (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role and underlying mechanisms of the long non-coding RNA (lncRNA) X inactive-specific transcript (XIST) in gastric cancer (GC).
methodsReal-time quantitative PCR (RT-qPCR), CCK-8, colony formation, flow cytometry, Transwell, and scratch assays were used to evaluate the biological effects of XIST and miR-124 in GC cells. Bioinformatics analysis and dual-luciferase reporter (DLR) assays identified interactions between XIST, miR-124, and STAT3. Western blotting and RT-qPCR assessed changes in downstream targets, while a xenograft tumor model evaluated the in vivo effects of XIST knockdown.
resultsXIST was significantly upregulated, and miR-124 was downregulated in GC tissues and cell lines, with the strongest effects observed in MGC803 cells. Knockdown of XIST or overexpression of miR-124 suppressed GC cell proliferation, colony formation, migration, invasion, and promoted apoptosis, effects that were reversed by miR-124 inhibitors. Bioinformatics and DLR assays confirmed that XIST directly targeted miR-124 and regulated STAT3 expression. XIST knockdown increased miR-124 levels, reducing STAT3, PD-1, PD-L1, N-cadherin, and MMP9 expression, while elevating E-cadherin levels; these effects were reversed by miR-124 inhibitors. Additionally, sh-STAT3 mitigated the pro-tumorigenic effects of pcDNA-XIST, confirming the regulatory relationship. In vivo, XIST knockdown suppressed tumor growth by increasing miR-124 expression.
conclusionXIST promotes STAT3 expression by competitively binding to miR-124, thereby promoting GC progression. Targeting the XIST/miR-124/STAT3 axis may represent a potential therapeutic strategy for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.